Celgene Joins Troubled MS Club With Refuse To File For Ozanimod From US FDA
Executive Summary
Other multiple sclerosis contenders – including Sanofi's Lemtrada, Acorda's Ampyra, and Merck KgAA's cladribine – have also been RTFed. Question now for Celgene is how long the delay will be.
You may also be interested in...
Keeping Track: First RMAT Approval On The Horizon; Big Weeks For Merck, Lilly And Celgene
The latest drug development news and highlights from our US FDA Performance Tracker.
FDA Backs Novartis MS Pill Mayzent With Broad Label
Mayzent is the first oral therapy proven to delay progression in patients with secondary progressive multiple sclerosis and Novartis pharma chief Paul Hudson tells Scrip its $88,500 list price will not affect access.
Stock Scan February 2018: Wet But Above Water
The market slump at the beginning of February affected virtually all of the stocks of the top 50 pharmaceutical companies. But unpredicted clinical successes or surprisingly good financials still kept a few companies above water.